| 1. |
- Bergmann, O., et al.
(författare)
-
The Age of Olfactory Bulb Neurons in Humans
- 2012
-
Ingår i: Neuron. - : Elsevier BV. - 0896-6273 .- 1097-4199. ; 74:4, s. 634-639
-
Tidskriftsartikel (refereegranskat)abstract
- Continuous turnover of neurons in the olfactory bulb is implicated in several key aspects of olfaction. There is a dramatic decline postnatally in the number of migratory neuroblasts en route to the olfactory bulb in humans, and it has been unclear to what extent the small number of neuroblasts at later stages contributes new neurons to the olfactory bulb. We have assessed the age of olfactory bulb neurons in humans by measuring the levels of nuclear bomb test-derived C-14 in genomic DNA. We report that C-14 concentrations correspond to the atmospheric levels at the time of birth of the individuals, establishing that there is very limited, if any, postnatal neurogenesis in the human olfactory bulb. This identifies a fundamental difference in the plasticity of the human brain compared to other mammals.
|
|
| 2. |
|
|
| 3. |
- Ligthelm, R. J., et al.
(författare)
-
Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: A randomised open-label parallel group four months comparison in patients with type 2 diabetes
- 2006
-
Ingår i: Experimental and Clinical Endocrinology & Diabetes. - : Georg Thieme Verlag KG. - 1439-3646 .- 0947-7349. ; 114:9, s. 511-519
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: To show that a thrice daily meal-time biphasic insulin aspart (BIAsp) treatment regimen is as efficacious as a 4 times daily basal-bolus regimen with human isophane insulin (NPH) and insulin aspart (IAsp). Methods: A multinational, randomised, open-label parallel-group trial in 394 patients with type 2 diabetes on a once or twice daily insulin regimen. Patients were randomised 1:1 to BIAsp or IAsp+NPH for 16 weeks. The BIAsp group was treated according to individual needs using BMI as a surrogate index of insulin resistance. Subjects administered BIAsp 70 (BMI < 30 kg/m(2)) or BIAsp 50 (BMI > 30 kg/m(2)) with breakfast and lunch and BIAsp 30 with dinner. The IAsp + NPH group injected IAsp at meals and NPH at bedtime as basal insulin. HbA(lc) levels after 16 weeks were compared between treatments using a predefined non-inferiority criterion of 0.4%. The incidence of BIAsp was non-inferior to that obtained by the IAsp+NPH (intention to treat [ITT]) population: diff, HbA(lc)-0.05%; 95% CI (-0.24; 0.14); per protocol (PP) population: diff, HbA(lc)-0.03%; 95% CI (-0.23; 0.16). Similar improvements in glycaemic control in both groups were confirmed by self-measured 8-point plasma glucose (PG) profiles, average and fasting PG concentrations, and average prandial PG increments. The incidence of adverse events and hypoglycaemic episodes was similar in the two treatment groups. Conclusions: A thrice daily meal-time BIAsp regimen is a suitable alternative to an intensified insulin regimen in people with inadequately controlled type 2 diabetes mellitus, and requires fewer daily injections than a basal-bolus therapy without compromising efficacy and safety.
|
|
